Clinart Brings Clinerion into MENA Region
Clinart will collaborate with Clinerion to expand its international network of healthcare institution partners in the Middle East and North Africa (MENA) region. Clinart will also offer Clinerion’s services to advance academic and sponsored research in MENA.
Clinart has a position as an innovative regional contract research organization offering a full-service end-to-end solution and access in the MENA region. Clinart will support Clinerion by linking sites and hospitals to the global network on Clinerion’s Patient Network Explorer (PNEx) platform. This will help hospitals in the region be more visible and accessible for global trial sponsors and attract more studies to the region. Clinart will also offer services derived from PNEx for the running of local real-world evidence studies and academic research.
The partnership supports Clinart’s vision to support patients and healthcare providers by making the region more visible to trial sponsors, attracting more international studies to the region, enabling capable local organizations to run real-world evidence projects, and facilitating local academic research across the region.
The collaboration will initially focus on the Gulf countries of the United Arab Emirates and Saudi Arabia. This will expand later to other countries in the region.
“We are very excited about the opportunity to partner with Clinerion in the MENA region,” says Alaa Assem, President & CEO of Clinart. “We believe that the region can benefit from this partnership through the improvement of visibility of the region on a global level. By providing better access to Real World Evidence data and analytics from the region, we can generate a better understanding of disease prevalence and treatment patterns in geographies which are currently underrepresented. We are strongly positioned to support Clinerion with this initiative and also to support the sites with establishing the required infrastructure and resources needed to successfully deliver.”
“Clinerion is thrilled to have a partner who can support us in our efforts to improve patient outcomes in the MENA region,” says Ian Rentsch, CEO of Clinerion. “Clinart has an excellent reputation and a network capable of making things happen.”
For more information go to www.clinerion.com
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
